A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer

The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses

(2018) Natalia Aptsiauri et al.   CURRENT OPINION IN IMMUNOLOGY

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

(2018) Scott J. Rodig et al.   Science Translational Medicine

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer

(2018) David Stenehjem et al.   OncoTargets and Therapy

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

(2017) Moshe Sade-Feldman et al.   Nature Communications

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

(2017) Scott Gettinger et al.   Cancer Discovery

HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape

(2017) Francisco Perea et al.   Oncotarget

Rejection versus escape: the tumor MHC dilemma

(2016) Federico Garrido et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The urgent need to recover MHC class I in cancers for effective immunotherapy

(2016) Federico Garrido et al.   CURRENT OPINION IN IMMUNOLOGY

MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2

(2016) De-Ning Ma et al.   Journal of Hematology & Oncology

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma

(2015) F. Sabbatino et al.   CLINICAL CANCER RESEARCH

Immunosuppressive cells in tumor immune escape and metastasis

(2015) Yang Liu et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

(2014) Z. Gatalica et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy

(2014) Yuichiroh Umemoto et al.   JOURNAL OF GASTROENTEROLOGY

Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma

(2013) Ana B. del Campo et al.   INTERNATIONAL JOURNAL OF CANCER

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidemiology and Risk Factors of Urothelial Bladder Cancer

(2012) Maximilian Burger et al.   EUROPEAN UROLOGY

Trends in Mortality From Urologic Cancers in Europe, 1970–2008

(2011) Cristina Bosetti et al.   EUROPEAN UROLOGY

Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors

(2010) Isabel Maleno et al.   IMMUNOGENETICS

Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells

(2010) Rafael Carretero et al.   INTERNATIONAL JOURNAL OF CANCER